Toremifene
- Generic Name
- Toremifene
- Brand Names
- Fareston
- Drug Type
- Small Molecule
- Chemical Formula
- C26H28ClNO
- CAS Number
- 89778-26-7
- Unique Ingredient Identifier
- 7NFE54O27T
Overview
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like tamoxifen, toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
Background
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like tamoxifen, toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
Indication
For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.
Associated Conditions
- Metastatic Breast Cancer
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2014/10/22 | Phase 1 | Completed | |||
2014/05/07 | Phase 3 | UNKNOWN | |||
2014/05/06 | Phase 2 | UNKNOWN | Fengxi Su | ||
2014/03/27 | Phase 3 | UNKNOWN | |||
2011/08/16 | Phase 3 | Completed | Satakunta Central Hospital | ||
2010/10/05 | Phase 3 | Withdrawn | |||
2007/09/26 | Phase 3 | Completed | Satakunta Central Hospital | ||
2007/02/21 | Phase 2 | Terminated | Japan Breast Cancer Research Network | ||
2005/12/21 | Phase 3 | Terminated | Intarcia Therapeutics | ||
2005/08/11 | Phase 3 | Completed |
FDA Approved Products
View More FDA Products
Sign in to access additional FDA-approved products with detailed regulatory information.
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
|---|
No FDA products found
No FDA products found for this drug
EMA Approved Products
View More EMA Products
Sign in to access additional EMA-approved products with authorization details.
Medicine Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
|---|
No EMA products found
No EMA products found for this drug
HSA Approved Products
View More HSA Products
Sign in to access additional HSA-approved products with regulatory information.
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval No. |
|---|
No HSA products found
No HSA products found for this drug
NMPA Approved Products
View More NMPA Products
Sign in to access additional NMPA-approved products with approval information.
Product Name | Approval No. | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
|---|
No NMPA products found
No NMPA products found for this drug
PPB Approved Products
Product Name | Registration Code | Company | Category | Sale Type | Reg. Date |
|---|
No PPB products found
No PPB products found for this drug
TGA Approved Products
View More TGA Products
Sign in to access additional TGA-approved products with licensing information.
Product Name | ARTG ID | Sponsor | Status | Reg. Date | Ingredient |
|---|
No TGA products found
No TGA products found for this drug